V. Leblond

Publications559
h-index67
Citations16,174
Highly Influential Citations522
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Treon
  • 611 Publications, 22,516 Citations
  • S. Stilgenbauer
  • 630 Publications, 28,744 Citations
  • Z. Hunter
  • 288 Publications, 6,093 Citations
  • I. Ghobrial
  • 643 Publications, 19,396 Citations
  • Publications
  • Influence
Post-transplant lymphoproliferative disorders
Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve uncontrolled proliferation of lymphoid cells as a consequence of extrinsic immunosuppression after organ… Expand
  • 249
  • 27
International prognostic scoring system for Waldenstrom macroglobulinemia.
Recently, many new drugs have been developed for the treatment of Waldenström macroglobulinemia (WM). To optimize the treatment according to the prognosis and to facilitate the comparison of trials,… Expand
  • 276
  • 17
Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
PURPOSE Organ recipients are at a high risk of posttransplant lymphoproliferative disorders (PTLD) as a result of immunosuppressive therapy. Most B-cell lymphomas are associated with Epstein-Barr… Expand
  • 336
  • 15
Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.
We report on the characteristics of 21 patients with hepatosplenic gammadelta T-cell lymphoma (HSgammadeltaTCL), an entity recognized since 1994 in the Revised European American Lymphoma (REAL)… Expand
  • 172
  • 15
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
PURPOSE To assess the feasibility and efficacy of intensive chemotherapy with hematopoietic stem-cell rescue (IC + HCR) in patients with refractory or recurrent primary CNS lymphoma (PCNSL) or… Expand
  • 261
  • 14
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
GAUGUIN evaluated the safety and efficacy of obinutuzumab (GA101) monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In phase 1 (dose escalation), 13 patients… Expand
  • 124
  • 12
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the…
PURPOSE To study the impact of high-dose therapy (HDT) with autologous stem-cell support in patients with symptomatic multiple myeloma (MM) between the ages of 55 and 65 years. PATIENTS AND METHODS… Expand
  • 341
  • 11
Bitumen morphologies by phase‐detection atomic force microscopy
Bitumen is a complex mixture of hydrocarbons for which microstructural knowledge is incomplete. In an effort to detail this microstructure, 13 bitumens were analysed by phase‐detection atomic force… Expand
  • 221
  • 11
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
BACKGROUND Post-transplantation lymphoproliferative disorder (PTLD) develops in 1-10% of transplant recipients and can be Epstein-Barr virus (EBV) associated. To improve long-term efficacy after… Expand
  • 248
  • 10
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
PURPOSE Prognostic studies of posttransplantation lymphoproliferative disorders (PTLDs) are hindered by the small number of cases at each transplant center. We analyzed prognostic factors and… Expand
  • 207
  • 9